Investing.com — Guggenheim Securities has highlighted its top pick in the pharmaceutical sector, with ABIVAX emerging as the firm’s leading recommendation amid improving sentiment around the company’s ulcerative colitis treatment candidate.
The brokerage’s latest sector analysis focuses on companies positioned for near-term catalysts and valuation recovery following recent market volatility in the biotech space.
1. ABIVAX – Guggenheim reiterated its Buy rating and $175 price target on the stock, maintaining it as its “Best Idea” in the pharmaceutical sector. The firm expects ABIVAX shares to rebound sharply as investor concerns over the safety profile of obefazimod, the company’s lead ulcerative colitis treatment, diminish following the latest long-term maintenance study update.
Guggenheim said newly reported rates of non-melanoma skin cancers and other malignancies fell within expected background ranges and were largely linked to pre-existing risk factors rather than the treatment itself. The brokerage noted that safety events were balanced across both the 25 mg and 50 mg doses, supporting the view that obefazimod does not carry a dose-dependent cancer risk. Guggenheim identified upcoming catalysts including a U.S. NDA filing expected in late 2026 and Phase IIb Crohn’s disease data anticipated in mid-2027.
The firm projects the stock could trade back into the $130-$150 range in the near term as safety concerns fade and investors refocus on the commercial opportunity for obefazimod in the inflammatory bowel disease market.
In recent developments, Abivax announced the pricing of an upsized $800 million public offering of American Depositary Shares. Following safety updates for its obefazimod candidate, Jefferies upgraded the company’s stock to Buy, and Citizens reiterated its Market Outperform rating.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
